FIT Biotech Oy
Company release December 18, 2017 at 4 pm EET                                 

FIT BIOTECH'S FINANCIAL CALENDAR IN 2018

FIT Biotech's full-year financial statements bulletin for 2017 is released on Thursday, March 1, 2018 and half-year interim report for January-June 2018 on Thursday, September 6, 2018.

The ordinary annual general meeting of shareholders is planned for Thursday, April 12, 2018. The company's Board of Directors will publish a separate notice to the AGM at a later date.

FIT Biotech's annual report will be published on the company's website at www.fitbiotech.fi during calendar week 11 / 2018.

FIT BIOTECH OY

Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
Tel: +358 40 840 6749
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media

Ads